Portfolio Entities

Centinel Spine, LLC

Centinel Spine is a revenue generating pure-play industry leader in anterior column restoration with the widest & deepest product portfolio (19 products, 4 PMA’s, 8 3D-Printed Fusion Implants, 3 Cervical TDR PMA Supplements, 2 Level Lumbar TDR approval). VBW has invested in Centinel to support its market expansion in the US market.

Explore

Companion Spine, LLC

Companion Spine focuses on Interventional Spine Pain Treatment. It has multiple products, addressing the fastest growing niches in spine pathologies: Degenerative Disc Disease (DDD) and Lumbar spinal stenosis (LSS). The Company generates revenues under the CE mark in Europe and is currently undergoing clinical trials to expand its product range in the US market. VBW has invested in Companion to support its clinical trials in the US and has provided an asset backed loan facility in the form of leasing Companion’s instrument sets to support its fast growth.

Explore

Synchron, Inc.

Synchron is a ground-breaking Brain Computer Interface (BCI) Company, founded by Tom Oxley and Nick Opie. The primary product is Stentrode, an 8mm endovascular stent that is implanted via minimally invasive procedure. The Stentrode interprets signals from the brain, for the treatment of neurological diseases, such as paralysis, epilepsy, and movement disorders without the need for an open brain surgery. Synchron was originally funded by University of Melbourne, DARPA and US Department of Defense. Among its notable investors are Arch Ventures, Khosla Ventures, Zefram (Jeff Bezos' Family Office) and Gates Frontier (William H. Gates' Investment Office). Synchron was granted FDA Breakthrough Device Designation followed by FDA IDE approval allowing clinical investigations (patient trials).

Explore

MCRA Holdings, LLC

Founded by Viscogliosi Brothers in 2004, MCRA is the world’s leading MedTech CRO firm with pristine track record of 18/18 PMA approvals and 5 FDA reversal approvals. The Company employs a a staff of 250+ and 21 former FDA branch chiefs and directors. MCRA commercialized 75 MedTech devices, has a 78% client retention rate across its 700 active clients. MCRA generates revenue throughout the product lifecycle including regulatory strategy and clinical research consultancy as well as provides quality & compliance, cybersecurity, and reimbursement services. MCRA investment brings VBW both financial and strategic benefits.

Explore

Rocket EMS, Inc.

Rocket EMS is a leading supply chain engineering and prototype manufacturing company, focusing on designing a cost-effective production solution in medical, telecom, defense and aerospace industries. The Company investigates and develops solutions to utilize the best equipment possible to eliminate manual labor and minimize defects to build optimum circuit boards. Rocket EMS’ production lines can place 2 million components daily. VBW has provided accounts receivable factoring facilities to Rocket EMS through its strategic partner, United Capital Financing Group LLC.

Explore

Spine Biopharma, LLC

Spine Biopharma is a clinical-stage company committed to developing non-surgical/nonopioid treatments that will reduce pain, restore function, and slow or stop pathological spinal disease progression. Spine BioPharma's lead candidate, SB-01 for Injection, is a first-in-class treatment of degenerative disc disease addressing a $90b market in the US alone.

Explore

ClinicaHealth Inc.

(dba. Inspire) is a web-based network of health communities focusing on 3,000 rare diseases. Inspire brought together over 100 National patient organisations building a community of 2.5m members, representing the largest cancer and rare disease communities in the US. The Company offers disease insights based on real-world-evidence data (RWE). The global RWE solutions market is estimated at $45b (2023) growing at a CAGR of 8.2%. This is a result of improvement in data analysis which reduces the burden of conducting lengthy and expensive clinical trials.

Explore

Press Release

January,9 2023

First-in-human SWITCH study demonstrates long-term safety of Stentrode neuroprosthesis device in patients with severe paralysis

This press release features multimedia. View the full release here:

Source: www.yahoo.com

Synchron Announces Publication of Brain-Computer Interface Clinical Trial in JAMA Neurology

NEW YORK, January 09, 2023--(BUSINESS WIRE)--Synchron, an implantable brain-computer interface (BCI) company, today announced the medical journal JAMA Neurology has published peer-reviewed, long-term safety results from a clinical study in four patients with severe paralysis implanted with Synchron’s first-generation Stentrode™, a neuroprosthesis device. The study found that it is possible to use the neuroprosthesis device to transmit neural signals from inside a blood vessel in the brain over a long-term period without any serious adverse events related to the device.

Press Release

January,9 2023

First-in-human SWITCH study demonstrates long-term safety of Stentrode neuroprosthesis device in patients with severe paralysis

This press release features multimedia. View the full release here:

Source: www.yahoo.com

Synchron Announces Publication of Brain-Computer Interface Clinical Trial in JAMA Neurology

NEW YORK, January 09, 2023--(BUSINESS WIRE)--Synchron, an implantable brain-computer interface (BCI) company, today announced the medical journal JAMA Neurology has published peer-reviewed, long-term safety results from a clinical study in four patients with severe paralysis implanted with Synchron’s first-generation Stentrode™, a neuroprosthesis device. The study found that it is possible to use the neuroprosthesis device to transmit neural signals from inside a blood vessel in the brain over a long-term period without any serious adverse events related to the device.

Portfolio Entities

Press Release

January,9 2023 First-in-human SWITCH study demonstrates long-term safety of Stentrode neuroprosthesis device in patients with severe paralysis

Synchron Announces Publication of Brain-Computer Interface Clinical Trial in JAMA Neurology

Press Release

January,9 2023 First-in-human SWITCH study demonstrates long-term safety of Stentrode neuroprosthesis device in patients with severe paralysis

Synchron Announces Publication of Brain-Computer Interface Clinical Trial in JAMA Neurology

January,9 2023

First-in-human SWITCH study demonstrates long-term safety of Stentrode neuroprosthesis device in patients with severe paralysis

January,9 2023

First-in-human SWITCH study demonstrates long-term safety of Stentrode neuroprosthesis device in patients with severe paralysis